Intellia Therapeutics, Inc. (NTLA)

Market Cap	835.39M
Revenue (ttm)	57.88M
Net Income (ttm)	-519.02M
Shares Out	103.52M
EPS (ttm)	-5.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,685,451
Open	8.27
Previous Close	8.40
Day's Range	8.03 - 8.43
52-Week Range	8.03 - 28.18
Beta	1.97
Analysts	Buy
Price Target	39.44 (+388.72%)
Earnings Date	May 8, 2025

About NTLA

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 403
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA
• Website: https://www.intelliatx.com

Financial Performance

In 2024, Intellia Therapeutics's revenue was $57.88 million, an increase of 59.55% compared to the previous year's $36.28 million. Losses were -$519.02 million, 7.86% more than in 2023.

Analyst Forecast

According to 18 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $39.44, which is an increase of 388.72% from the latest price.

Price Target

$39.44

(388.72% upside)

Analyst Consensus: Buy